Profusa is no longer a biosensor commercialization story in any practical sense. The Berkeley company that merged out of a special-purpose acquisition vehicle last summer has spent the second quarter proving that the Lumee tissue-chemistry platform cannot fund itself. Cash at mid-year was $719 thousand against a working-capital hole of roughly $27 million, and management again recorded substantial doubt about continuing as a going concern. The live debate is whether the Nasdaq listing can be kept long enough to absorb G3 Vision Labs, a commercial toxicology-lab group, before the residual common claim is diluted into irrelevance.
What changed is not a product launch. It is a control change and a recapitalization script. In late July the board installed Jack Stover as executive chairman and chief executive, moved founder Ben Hwang to president, and signed an option to buy G3 Vision Labs and its certified laboratory subsidiaries. Those labs serve addiction-treatment, pain-management, and behavioral-health providers. Management later pointed to a midsummer equity rebuild near $28 million after the option accounting and after creditors signed exchange agreements covering $10.7 million of claims. That rebuild is paper equity, not cash. The operating company still burned cash and still posted a second-quarter net loss that was driven more by convertible-note fair-value swings and financing costs than by the laboratory or the sensor.
Second-quarter net loss widened to $8.8 million from a much smaller year-ago deficit. First-half operating cash use reached $5.2 million. Three reverse splits during the year, a late quarterly filing, unremediated control weaknesses, and a one-year Nasdaq panel monitor all sit on top of that print. The question for the next several months is simple. Either the G3 option closes on audited numbers and a $30 million financing, or the listing vehicle runs out of time with an empty sensor franchise and a still-unfunded laboratory deal.